Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Immunol.

Sec. B Cell Biology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1609862

Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review

Provisionally accepted
Kun  KouKun KouQiaolin  ZhouQiaolin ZhouDu  LijunDu LijunFang  XuFang Xu*
  • Department of Hematology, Mianyang Central Hospital, Mianyang, sichuan,China, Mianyang, China

The final, formatted version of the article will be published soon.

Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Multiple clinical studies have shown that compared with rituximab combined with chemotherapy, obinutuzumab combined with chemotherapy can significantly improve the progression-free survival (PFS) of patients, effectively reduce the risk of disease progression, and improve patient prognosis. The main adverse effects of obinutuzumab include infusion reactions, myelosuppression, infection, cardiotoxicity, tumor lysis syndrome (TLS), etc., and in rare cases it may induce thrombocytopenia. However, so far there are few reports on "obinutuzumab-induced acute thrombocytopenia" (OIAT), especially severe cases. Here, we report a case of acute severe OIAT and review the literature to explore the management of this rare but life-threatening complication. The case is a 28-year-old young man who was diagnosed with stage IV follicular lymphoma and achieved remission after 8 cycles of R-CHOP chemotherapy. Later, he developed severe acute thrombocytopenia during maintenance treatment with obinutuzumab monotherapy, the patient's platelet count dropped from 191×10^9/L to 2×10^9/L on the 3rd day after the initial application, and severe thrombocytopenia occurred after multiple subsequent applications of obinutuzumab. OIAT is a rare but life-threatening complication. We should be aware of this adverse event and raise awareness about it.

Keywords: follicular lymphoma, Obinutuzumab, Severe, acute, Thrombocytopenia

Received: 11 Apr 2025; Accepted: 04 Aug 2025.

Copyright: © 2025 Kou, Zhou, Lijun and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Fang Xu, Department of Hematology, Mianyang Central Hospital, Mianyang, sichuan,China, Mianyang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.